WO2006095457A1 - Agent therapeutique pour les tumeurs malignes et aliment ou boisson le contenant - Google Patents

Agent therapeutique pour les tumeurs malignes et aliment ou boisson le contenant Download PDF

Info

Publication number
WO2006095457A1
WO2006095457A1 PCT/JP2005/012747 JP2005012747W WO2006095457A1 WO 2006095457 A1 WO2006095457 A1 WO 2006095457A1 JP 2005012747 W JP2005012747 W JP 2005012747W WO 2006095457 A1 WO2006095457 A1 WO 2006095457A1
Authority
WO
WIPO (PCT)
Prior art keywords
therapeutic agent
malignant tumor
food
treatment
tumor therapeutic
Prior art date
Application number
PCT/JP2005/012747
Other languages
English (en)
Japanese (ja)
Inventor
Michio Tani
Original Assignee
Michio Tani
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Michio Tani filed Critical Michio Tani
Publication of WO2006095457A1 publication Critical patent/WO2006095457A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L31/00—Edible extracts or preparations of fungi; Preparation or treatment thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L27/00—Spices; Flavouring agents or condiments; Artificial sweetening agents; Table salts; Dietetic salt substitutes; Preparation or treatment thereof
    • A23L27/10—Natural spices, flavouring agents or condiments; Extracts thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L27/00—Spices; Flavouring agents or condiments; Artificial sweetening agents; Table salts; Dietetic salt substitutes; Preparation or treatment thereof
    • A23L27/30—Artificial sweetening agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/07—Basidiomycota, e.g. Cryptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/534—Mentha (mint)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/75—Rutaceae (Rue family)
    • A61K36/752—Citrus, e.g. lime, orange or lemon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L21/00—Marmalades, jams, jellies or the like; Products from apiculture; Preparation or treatment thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L7/00—Cereal-derived products; Malt products; Preparation or treatment thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Definitions

  • the present invention relates to a therapeutic agent for malignant tumors (cancer, leukemia, etc.) and a food or drink containing the same.
  • a malignant tumor therapeutic agent comprising a mixture obtained by mixing shiitake mushrooms, maitake mushrooms, lemon balm, mint and stevia as active ingredients, and a food and drink containing the same.
  • Cancer and AIDS are intractable diseases feared all over the world. Among them, cancer accounts for about 30% of the mortality rate in Japan, and it is difficult to treat even with the three major medical treatments (surgery, radiation therapy, and anticancer drugs).
  • the three major medical treatments surgery, radiation therapy, and anticancer drugs.
  • a cancer therapeutic agent that develops a certain curative effect in vitro or in animal experiments has been developed, it may be difficult to cure the cancer without side effects if it is used in the human body. Reality.
  • At least one koji selected from Bunashimeji, Shitake, Maitake, Hatakeshimeji, and Enokitake is extracted with water, a hydrophilic solvent, or a mixed solvent thereof.
  • An anticancer drug containing a physiologically active substance as an active ingredient can enhance the anticancer effect of a chemotherapeutic agent while having high safety, It is known that daily ingestion can prevent cancer (see, for example, Patent Document 1).
  • this anticancer drug is only for preventing cancer and enhancing the anticancer effect of the chemotherapeutic agent, and there is no description of the anticancer effect in this drug itself.
  • a solution obtained by treating moss such as Ganoderma and Agaritas, Azabushitake, Enokidake, Shiitake, Maiko, Shimeji, Kiso, etc. with a strong alkali to be deacetylated and treated with a strong acid to form a deoxygenated bridge Separated and mixed to neutralize the solution, added calcium chloride to the deacetylated solution, and precipitated calcium j8-glucan, and concentrated the solution to recover the polysaccharide.
  • soybeans, okara powder, and rice cake powder and then dry powder to make ascorbic acid and citrate mixed with ascorbic acid calcium taenate j8-glucan powder.
  • anti-diabetic and anti-hepatic agents are anti-diabetics characterized by mixing with stevia, rahan, chitin chitosan and amino acids, ganoderma spore, persimmon, green tea powder, non-chlorella, persimmon-phosphorus, pyrethroid.
  • this anticancer agent is obtained by treating shiitake mushrooms or maiko with a strong alkali or the like, and is different from the malignant tumor therapeutic agent of the present invention.
  • peppermint-derived gera-lunaric acid synthase protein and monoterpene synthase protein are introduced into cancerous cells and are different from the malignant tumor therapeutic agent of the present invention.
  • Patent Document 1 Japanese Unexamined Patent Publication No. 2003-231644
  • Patent Document 2 JP 2004-10605 A
  • Patent Document 3 Japanese Translation of Special Publication 2001-520004
  • the present invention is a malignant tumor therapeutic agent that has high safety even if it is regularly used for a long time without serious side effects as seen in drugs because it is made from food materials.
  • the purpose of this is to provide food and drinks containing it.
  • the object is achieved by a therapeutic agent for malignant tumors comprising as an active ingredient a mixture obtained by mixing shiitake mushroom, maitake, lemon balm, mint and stevia.
  • the object is achieved by a food or drink containing the malignant tumor therapeutic agent.
  • the therapeutic agent for malignant tumor of the present invention and food and drink containing the same show remarkable effects for malignant tumor treatment by continuous use. However, since it is made from food materials, it is highly safe without the serious side effects seen in radiation therapy and acupuncture. In addition, the food and drink of the present invention can continuously treat malignant tumors in daily life.
  • the human body usually has at least 500 to 1000 or more cancer cells, even if it is a completely healthy person.
  • the reason why it does not develop as a carcinoma is the ability of the immune function that is originally provided to quickly find cancer cells as abnormal cells and extinguish them.
  • Improving immune function quality 2) Enhancing immune function 3) Coordinating immune function and improving its environment It is necessary to do this. That is, the therapeutic agent for malignant tumor prepared as in the present invention is effective for enhancing the repair of these immune functions.
  • the therapeutic agent for malignant tumor of the present invention comprises a mixture obtained by mixing shiitake mushroom, maitake, lemon balm, mint and stevia as an active ingredient.
  • the weight ratio of shiitake mushroom, maitake, lemon balm, mint and stevia is 2 to 5: 2 to 5: 1 to 4: 0.
  • a treatment effect of 0: 5 to 2 is preferred, and a treatment effect of 3: 3: 2: 1: 1 is particularly preferred.
  • shiitake mushroom, maitake, lemon balm, mint, stevia, shimeji mushroom, celery seed and chiaichi may further contain at least one selected from the group consisting of shimeji mushroom, celery seed and chia building strength.
  • the weight ratio of the building is 2-5: 2-5: 1-4: 0.5-2: 0.5-2: 2-5: 1-4: 1-4 in each dry state An effect is obtained, and 3: 3: 2: 1: 1: 1: 3: 2: 2 is particularly preferred, and a therapeutic effect is obtained.
  • a mixture of finely chopped mixture may be taken as it is, but preferably an extract extracted with hot water is taken.
  • the mixture is in a dry powder state and a dry powder that has been processed into a good shape or a hot water extracted extract is taken.
  • the above mixture or a dried product thereof may be subjected to hot water extraction as it is.
  • the practical surface force may be further crushed and pulverized.
  • the weight ratio between the hot water used as the extraction solvent and the dried product is not particularly limited, but is 10 to 50 times the amount of hot water compared to the dried product, particularly 20 to 40 weights in terms of extraction operation and efficiency. Double hot water is preferred.
  • the extraction temperature is efficient at high temperature, and 70-95 ° C is particularly good.
  • the extraction time should be 30 minutes or more and 60 minutes or less under normal pressure.
  • the extraction may be performed under pressure or normal pressure. Particularly preferable extraction conditions are an atmospheric pressure, an extraction temperature in the range of 75 to 90 ° C, and an extraction time in the range of 30 to 60 minutes.
  • the dosage of the therapeutic agent for malignant tumor of the present invention may vary depending on the disease state, the age of the patient, etc., but it is usually taken after extracting with hot water, preferably 10-30 g as the weight of dry matter per day. In this case, it is appropriate to extract this amount with 200-500g of hot water.
  • hot water extract is spray-dried or freeze-dried and taken as an extract powder, granule, tablet, etc.
  • the weight of the powdered product is suitably 3.0 to 6. Og.
  • the malignant tumor therapeutic agent of the present invention includes, for example, soups, various beverages (juice, alcohol, mineral water, etc.), confectionery (gum, candy, chocolate, snack, jelly, etc.), foods ( Soba, udon, ramen, etc.) and other general foods, health foods, nutritional supplements It can be set as the food / beverage products of this invention by mix
  • the concentration of the therapeutic agent for malignant tumor in the food and drink of the present invention can be appropriately changed depending on the type of food and drink. Normally, when a dry powder is mixed, the concentration per day When hot water extract is mixed as a spray-dried or freeze-dried extract powder, the daily intake is 2.2.0-12 when blended so that the intake is 10-50 g, preferably 20-30 g. . Og, preferably 3.0 to 6. Og. In addition, about the said density
  • Shiitake mushroom powder 3.0g Maitake mushroom powder 3.0g, Lemon balm mushroom powder 2.0g, Mint mushroom mushroom powder 1.
  • Og and stevia mushroom mushroom powder 1.0g, Shimeji mushroom mushroom moulder powder 3.0m The dry extract obtained by mixing with Ochiya Building 2. Og was coarsely pulverized and extracted with 300 g of hot water at about 90 ° C for 40 minutes.
  • Shiitake dry powder 2.0g Maitake dry powder 2.0g, Lemon balm dry powder 1.0g, Mint dry powder 0.5g, Stevia dry powder 0.5g, Shimeji dry powder 2.0g, Celery seed dry powder 1.
  • Comparative Example 1 The extract obtained by roughly pulverizing 10 g of dried shiitake mushroom and extracting with 200 g of hot water at about 90 ° C. for 40 minutes was designated as Comparative Example 1.
  • Example 1 The clinical test results for confirming the therapeutic effect of the product of the present invention (Example 1) are as follows.
  • Treatment started 1. Five months ago: Diagnosis of spleen cancer was made with abdominal blunting as the first symptom, but at that time, it had already developed diabetes due to cancer infiltration throughout the spleen. He was admitted to the Sakai Cancer Center for scrutiny, and jaundice appeared. This is because the cancer invading the spleen reached the bile duct and blocked the biliary tract. The jaundice index in the blood increased and the blood alkaline phosphatase showed more than 1,500. Two metastases with a diameter of 4 cm or more have already been found (Figs. 1 and 2).
  • the therapeutic agent for malignant tumor of Example 1 was administered (the dosage of the therapeutic agent was 25 g as dry matter weight per day). I started by improving the quality of immunity. From our experience, “ki” in the Orient and “vital energy” in Europe have a very positive effect on the immune function of the human body. In this example, the power can be defeated in about 50 days, and it has progressed relatively smoothly since then.
  • Eastern medical immunotherapy is characterized by the disappearance and improvement of the primary cancer site and the metastatic site to any part of the body at almost the same time. Note: This is fundamentally different from the therapeutic effect of only the treated area such as embolization or radiotherapy.
  • Example 2 The clinical test results for confirming the therapeutic effect of the product of the present invention (Example 2) are as follows.
  • Treatment start point (approximately 1 year after surgery): Administration of the malignant tumor therapeutic agent of Example 2 was started.
  • the dose of the therapeutic agent was 25 g as dry matter weight per day. Life expectancy about 1-2 years, side effects due to radiation, and the ability to live mentally and physically unstable with strong general malaise and reduced vitality in life I regained my spirit and started eagerly working on treatment.
  • Example 4 The clinical test results for confirming the therapeutic effect of the product of the present invention (Example 4) are as follows.
  • Treatment start point From there, the treatment was changed to the treatment for administration of the malignant tumor therapeutic agent of Example 4. During the visit, he was accompanied by his family and visited with a wheelchair because of his general malaise and walking pain and wobble in his left leg. I decided to start treatment.
  • the negative effects on the immune system due to the above-mentioned chemotherapy are the strength and strength of immunity.
  • the dose of the therapeutic agent was 25 g as dry matter weight per day.
  • Example 1 Using the malignant tumor therapeutic agent obtained in Example 1, a candy containing 6.0% by weight of the malignant tumor therapeutic agent was prepared according to a conventional method.
  • Example 6 Using the therapeutic agent for malignant tumor obtained in Example 2, tea containing 6.0% by weight of the therapeutic agent for malignant tumor was prepared according to a conventional method.
  • the food / beverage products containing the malignant tumor therapeutic agent of the above-mentioned example can be easily ingested in daily life and can effectively treat malignant tumors without side effects.
  • FIG. 1 CT image before treatment with this drug.
  • FIG. 3 is a graph showing changes in tumor marker Kun-2.
  • FIG. 4 CT image about 6 months after treatment with this drug.
  • FIG.5 CT image about 6 months after treatment with this drug.
  • FIG. 6 is a CT image showing a recurrent tumor before treatment.
  • FIG. 7 is a CT image showing a recurrent tumor at the start of treatment.
  • FIG. 8 is a CT image showing disappearance of a cancer tumor after treatment with this drug.
  • FIG. 9 is a bone scintigraphic photograph of multiple myeloma before treatment with this drug.
  • FIG. 10 is a bone scintigraphic photograph of multiple myeloma one year after treatment with this drug.
  • FIG. 11 A bone scintigraphic photograph of multiple myeloma about 3 and a half years after treatment with this drug.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medical Informatics (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Epidemiology (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Nutrition Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Non-Alcoholic Beverages (AREA)

Abstract

L’invention concerne un agent thérapeutique pour les tumeurs malignes ainsi qu’un aliment ou une boisson contenant cet agent. L’utilisation de matières alimentaires, dont l’innocuité a été prouvée, a permis de révéler que cet agent est sans risque et dépourvu d’effets secondaires même lorsqu’il est administré régulièrement sur une période prolongée. L’agent thérapeutique pour les tumeurs malignes renferme en tant que principe actif un mélange obtenu en associant un champignon shiitake, du Grifola frondosa, de la citronnelle, de la menthe et du stevia.
PCT/JP2005/012747 2005-03-04 2005-07-11 Agent therapeutique pour les tumeurs malignes et aliment ou boisson le contenant WO2006095457A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2005061679 2005-03-04
JP2005-061679 2005-03-04
JP2005-179976 2005-06-20
JP2005179976A JP2006273835A (ja) 2005-03-04 2005-06-20 悪性腫瘍治療剤及びそれを含む飲食品

Publications (1)

Publication Number Publication Date
WO2006095457A1 true WO2006095457A1 (fr) 2006-09-14

Family

ID=36953063

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2005/012747 WO2006095457A1 (fr) 2005-03-04 2005-07-11 Agent therapeutique pour les tumeurs malignes et aliment ou boisson le contenant

Country Status (2)

Country Link
JP (1) JP2006273835A (fr)
WO (1) WO2006095457A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013069821A1 (fr) * 2011-11-10 2013-05-16 Michio Tani Agent thérapeutique contre une tumeur maligne et aliment et boisson comprenant cet agent
US20160000855A1 (en) * 2013-02-18 2016-01-07 Arkray, Inc. Oxidized protein hydrolase activity enhancing agent

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08176002A (ja) * 1994-12-27 1996-07-09 Kao Corp 細胞接着抑制剤
JPH09238697A (ja) * 1996-03-08 1997-09-16 Yukiguni Maitake:Kk マイタケから抽出した抗腫瘍物質
JPH11302191A (ja) * 1998-04-20 1999-11-02 Eishogen:Kk ハタケシメジ抽出物を活性成分とする免疫賦活剤及び抗腫瘍剤
JP2000159682A (ja) * 1998-09-17 2000-06-13 Kozo Niwa 生薬の抗腫瘍活性強化方法、抗腫瘍活性強化生薬含有組成物、生薬処理の抗腫瘍有効性評価方法、および生薬の抗腫瘍有効性評価方法
JP2000157203A (ja) * 1998-11-27 2000-06-13 Kobayashi Pharmaceut Co Ltd シイタケ菌糸体抽出物を含むγδＴ細胞免疫活性増強剤
JP2000159686A (ja) * 1998-11-27 2000-06-13 Kobayashi Pharmaceut Co Ltd シイタケ菌糸体抽出物由来のｌａｋ活性増強用製剤
US20020137799A1 (en) * 2000-11-08 2002-09-26 Gould Michael N. Monoterpenes and sesquiterpenes as chemotherapeutic and radiation sensitizers and immunomodulators
JP2004010605A (ja) * 2002-06-04 2004-01-15 Tomoji Tanaka 脱アセタールと脱酸素橋化を行った茸類と発酵霊芝胞子に他の混合物を使った癌予防健康食品と制癌剤及び添加飼料
JP2004307453A (ja) * 2003-04-07 2004-11-04 Bhn Kk 血管新生阻害剤及びその利用
JP2004331641A (ja) * 2003-05-08 2004-11-25 Tomoji Tanaka 霊芝胞子にリグニン．タンニン柿渋等を入れた混合食品と飼料添加剤と抗肺炎ビールス剤

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08176002A (ja) * 1994-12-27 1996-07-09 Kao Corp 細胞接着抑制剤
JPH09238697A (ja) * 1996-03-08 1997-09-16 Yukiguni Maitake:Kk マイタケから抽出した抗腫瘍物質
JPH11302191A (ja) * 1998-04-20 1999-11-02 Eishogen:Kk ハタケシメジ抽出物を活性成分とする免疫賦活剤及び抗腫瘍剤
JP2000159682A (ja) * 1998-09-17 2000-06-13 Kozo Niwa 生薬の抗腫瘍活性強化方法、抗腫瘍活性強化生薬含有組成物、生薬処理の抗腫瘍有効性評価方法、および生薬の抗腫瘍有効性評価方法
JP2000157203A (ja) * 1998-11-27 2000-06-13 Kobayashi Pharmaceut Co Ltd シイタケ菌糸体抽出物を含むγδＴ細胞免疫活性増強剤
JP2000159686A (ja) * 1998-11-27 2000-06-13 Kobayashi Pharmaceut Co Ltd シイタケ菌糸体抽出物由来のｌａｋ活性増強用製剤
US20020137799A1 (en) * 2000-11-08 2002-09-26 Gould Michael N. Monoterpenes and sesquiterpenes as chemotherapeutic and radiation sensitizers and immunomodulators
JP2004010605A (ja) * 2002-06-04 2004-01-15 Tomoji Tanaka 脱アセタールと脱酸素橋化を行った茸類と発酵霊芝胞子に他の混合物を使った癌予防健康食品と制癌剤及び添加飼料
JP2004307453A (ja) * 2003-04-07 2004-11-04 Bhn Kk 血管新生阻害剤及びその利用
JP2004331641A (ja) * 2003-05-08 2004-11-25 Tomoji Tanaka 霊芝胞子にリグニン．タンニン柿渋等を入れた混合食品と飼料添加剤と抗肺炎ビールス剤

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ACHI W. ET AL.: "Ursolic Acid no Shikyu Naimaku Saibo ni Taisuru Koshuyo Koka to Sayo Kijo", JAPAN SOCIETY FOR BIOSCIENCE, BIOTECHNOLOGY, AND AGROCHEMISTRY KOEN YOSHISHU, vol. 2002, 2002, pages 23, 2-3EA05, XP003002065 *
ALLAHVERDIYEV A. ET AL.: "Investigation of the anticarcinogenic effect of the essential oil of Melissa officinalis L", PHARMACEUTICAL PHARMACOLOGICAL LETTERS, vol. 11, no. 1, 2001, pages 26 - 29, XP003002064 *
SALEH M.M.: "Cytotoxicity and in vitro effects on human cancer cell lines of volatiles of Apium graveolens var. filicinum", PHARMACEUTICAL PHARMACOLOGICAL LETTERS, vol. 8, no. 2, 1998, pages 97 - 99, XP008041812 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013069821A1 (fr) * 2011-11-10 2013-05-16 Michio Tani Agent thérapeutique contre une tumeur maligne et aliment et boisson comprenant cet agent
JP2013103886A (ja) * 2011-11-10 2013-05-30 Michishi Tani 悪性腫瘍治療剤及びそれを含む飲食品
CN104039335A (zh) * 2011-11-10 2014-09-10 谷美智士 恶性肿瘤治疗剂及包含该恶性肿瘤治疗剂的食物和饮料
US20160000855A1 (en) * 2013-02-18 2016-01-07 Arkray, Inc. Oxidized protein hydrolase activity enhancing agent

Also Published As

Publication number Publication date
JP2006273835A (ja) 2006-10-12

Similar Documents

Publication Publication Date Title
CN104431586A (zh) 一种仔猪配合饲料及其制备方法
CN103386078B (zh) 一种中药组合物在制备治疗结肠癌药物中的应用
JP2001172192A (ja) 治療食
CN106723075A (zh) 一种双参沙棘g蛋白肉苁蓉锌硒制剂及其制备方法
EP1583547B1 (fr) Ingredients anti-obesite obtenus a partir de plantes medicinales et leur composition
WO2006095457A1 (fr) Agent therapeutique pour les tumeurs malignes et aliment ou boisson le contenant
CN106421374A (zh) 治疗糖尿病的中药组合物及其使用方法
WO2005056022A1 (fr) Composition ameliorant l'enteropathie
KR100237168B1 (ko) 동과, 팥, 다엽 및 상지의 추출물을 함유하는 비만조절용 건강식품
JP2008531552A (ja) 熟地黄と五加皮の混合生薬材抽出物及びそれを有効成分とする骨粗鬆症予防及び治療用組成物
CN106924539A (zh) 一种治疗消化性溃疡、胃炎及反流性食管炎的中药制剂及其制备方法和应用
JP4681363B2 (ja) 悪性腫瘍治療剤及びそれを含む飲食品
JP2013103886A (ja) 悪性腫瘍治療剤及びそれを含む飲食品
JPH0761953B2 (ja) 免疫力増強・体質改善剤の製造法
CN106937990B (zh) 一种外用排毒消炎组合物
US7998476B2 (en) Method of treatment using Aspergillus oryzae protease
CN108066363A (zh) 一种养肝强身组合物
CN103431277B (zh) 一种供创伤、手术患者食用的五谷杂粮全营养配方食品
CN103006973B (zh) 一种养胃保健品制剂及其制作方法
CN102805765B (zh) 一种治疗跌打损伤接骨胶囊
JPH06345660A (ja) ナトリウム吸収阻害剤、ナトリウム吸収阻害飲食物および動物用飲食物
CN106237245B (zh) 一种治疗急慢性腹泻的中药组合物及其制剂和应用
CN117357584A (zh) 一种治疗慢性心力衰竭的中药组合物，其制备方法及应用
CN113648391A (zh) 一种治疗白血病的中药组合物
CN104491263A (zh) 食道癌活血化瘀药剂及制备方法

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

WWW Wipo information: withdrawn in national office

Country of ref document: RU

122 Ep: pct application non-entry in european phase

Ref document number: 05765523

Country of ref document: EP

Kind code of ref document: A1

WWW Wipo information: withdrawn in national office

Ref document number: 5765523

Country of ref document: EP